

## SHORT REPORT

### OPEN ACCESS

Full open access to this and thousands of other papers at <http://www.la-press.com>.

## Apolipoprotein E Allelic Frequency Altered in Women with Early-onset Breast Cancer

Tirtsa Porrata-Doria<sup>1</sup>, Jaime L. Matta<sup>1</sup> and Summer F. Acevedo<sup>1,2</sup>

<sup>1</sup>Department of Physiology, Pharmacology, and Toxicology, <sup>2</sup>Psychology Program, Ponce School of Medicine, Ponce, Puerto Rico. Corresponding author email: [sacevedo@psm.edu](mailto:sacevedo@psm.edu)

**Abstract:** Among women, the most prevalent type of cancer is breast cancer, affecting 1 out of every 8 women in the United States; in Puerto Rico, 70 out of every 100,000 will develop some type of breast cancer. Therefore, a better understand of the potential risk factors for breast cancer could lead to the development of early detection tools. A gene that has been proposed as a risk factor in several populations around the world is Apolipoprotein E (apoE). ApoE functions as a mechanism of transport for lipoproteins and cholesterol throughout the body, with 3 main isoforms present in humans (apoE2, apoE3, and apoE4). Whether or not apoE4 is a risk factor for breast cancer remains controversial. Previous studies have either included test subjects of all ages (20–80) or have focused on late-onset (after age 50) breast cancer; none has concentrated specifically on early-onset (aged 50 and younger) breast cancer. The objectives of this study was to examine (in a Puerto Rican population) the differences in the relative frequency of occurrence of apoE4 in non-breast cancer versus breast cancer patients and to examine, as well, the potential differences of same in early- versus late-onset patients. We found an increased frequency of apoE4 (odds ratio 2.15) only in early-onset breast cancer survivors, which is similar to the findings of those studies that combined or adjusted for age as well as for an association between apoE4 and decreased tumor size. ApoE is also a potential risk factor for long-term cognitive effects after chemotherapy and affects response to hormone replacement. Our data supports the theory that knowing the apoE genotype of women who are at risk of developing breast cancer may be beneficial, as such knowledge would aid in the prediction of tumor size and the development of treatment regimens.

**Keywords:** breast cancer, apoe, puerto rican, risk factor, early-onset

*Breast Cancer: Basic and Clinical Research* 2010:4 43–48

This article is available from <http://www.la-press.com>.

© the author(s), publisher and licensee Libertas Academica Ltd.

This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.



## Cancer Surveillance Report

Accounting for 20% of all malignancies in women (globally), breast carcinoma (BC) is the most common cancer to affect this population.<sup>1-3</sup> The estimated annual incidence of BC worldwide is about one million cases.<sup>2,3</sup> Studies conducted by the American Cancer Society indicate that there are 2.5 million breast cancer survivors in the United States (2005), which number is expected to increase by 31% by 2015.<sup>2</sup> This means that 1 out of every 8 women is expected to have some form of breast cancer in her lifetime.

Extensive research has been conducted in the last 10 years regarding potential genetic risk factors, one of those genes being apolipoprotein E (apoE).<sup>4-8</sup> The apoE gene is responsible for the metabolism of lipoproteins and cholesterol as well as for the distribution of these (metabolized) substances throughout the body.<sup>9</sup> There are 3 main alleles found in humans, apoE2, apoE3, and apoE4. Changes in apoE4 allelic frequency are normally examined in association with the increased risk of age-related cognitive impairments and the development of Alzheimer's disease (AD), particularly in females.<sup>6-8</sup> African Americans and Caribbean and Mexican Hispanics also display similar risk factors associated with the apoE4 allele, such as lowering the age of onset of sporadic AD and reducing memory performance in individuals 65 years and older.<sup>6-8</sup> However, changes in apoE4 allelic frequency are not limited to those with neuronal conditions.

Various investigations also indicate that apoE4 allelic frequency is altered in various types of cancer including breast cancer and early onset prostate cancer.<sup>6-8</sup> The potential risk in the development of breast cancer and odds ratios appears to depend on the populations examined. In women from Turkey and Finland, either with or without breast cancer, no differences appear in apoE4 allelic frequency.<sup>6-8</sup> In contrast, there are indications of an increase in apoE4 allelic frequency in women from Taiwan, Italy, and Africa.<sup>6-8</sup> One common limitation in most of the studies that hypothesize that apoE may be a potential risk factor in the development of breast cancer is that they did not include subjects who developed breast cancer at or before the age of 50.<sup>6-8</sup> Studies that included young subjects with early onset of breast cancer grouped all patients together or adjusted for age

(with ages ranging from the 20s to the 80s).<sup>6-8</sup> Those studies that used broad age ranges were more likely to report an association between being an apoE4 carrier and having a risk for breast cancer.<sup>6-8</sup> Therefore, an explanation for the discrepancies that appear in the association of apoE4 and breast cancer risk is the inclusion of early-onset breast cancer patients. Understanding the genetics of early-onset breast cancer would increase the probability of early detection of tumors before the need for invasive treatments.

As of 2003, the incidence of women with breast cancer in Puerto Rico was 78 per 100,000, with 50.4 women per 100,000 receiving invasive treatment including surgery and/or chemotherapy.<sup>10-12</sup> The mortality rate in 2003 was 16 per 100,000, resulting in approximately 1,540 deaths that year, making it the most prevalent, most commonly diagnosed cancer and the highest cause of cancer-related death among Puerto Rican women.<sup>12</sup> The overall incidence of breast cancer is similar to levels reported in the United States (across all ages).<sup>12</sup> However, the probability of Puerto Ricans developing the more advanced stage-4 cancers is 3.6 times higher, and Puerto Rican women have a 1.6 times greater risk of mortality compared to Hispanic whites.<sup>1</sup> These rates are similar to other Hispanic white populations including Mexicans.<sup>1</sup> Breast Cancer is the most common form of cancer for Puerto Rican women, both for those residing on the island and for those in the mainland United States.<sup>13</sup>

In regards to genetics, Puerto Ricans and other Caribbean Hispanics are very diverse and include Hispanic (European and South American), Caucasian, and African genes, along with other native groups. Studies involving the haplogroups of 800 mitochondrial DNAs (both randomly and systematically selected) suggest that the Puerto Rican population is genetically mixed, composed primarily of African, European and Amerindian genes.<sup>14,15</sup> This population represents individuals affected by multiple ancestral genetic pools with implications that genetic risk factors are not specific to one ethnic group. The purpose of this study was to examine whether apoE allelic frequency was altered in Puerto Rican women and whether there were differences in the frequency with which this allele appeared in women with early-onset as compared to those with late-onset breast cancer. Spreadsheets containing the obtained data were converted and analyzed using SPSS 15.0 software. Statistical differences

between groups were determined by ANOVA, the presence of apoE (apoE4 carrier vs. non-apoE4 carrier) and/or individuals diagnosed with breast cancer as the between-participant factors, followed by Tukey-Kramer post-hoc tests when appropriate. A Student's *t*-test was used to analyze differences between non-breast cancer and breast cancer subjects separated by age group (21–50, 51–89).

The collection of samples used in this study was approved by the IRB of the Ponce School of Medicine, Ponce, PR, and participating hospitals for use in a large scale case-control study for which one of the co-authors (J.L.M.) is the PI. An informed consent was administered to each participant (cases and controls) for interviewing, drawing blood samples and, for cases, obtaining tumor material and pathology reports. The design for this case-control study called for utilizing incident cases; it began with recently diagnosed, histopathologically confirmed breast carcinoma cases. These recently diagnosed cases had not received chemotherapy and/or radiotherapy. These cases were recruited primarily through clinicians in the cities of Ponce, San Juan, and Yauco as well as other selected collaborating cities throughout Puerto Rico representing approximately 58 out of the 78 municipalities (counties) on the island. Recruitment sites included the Ponce School of Medicine Outpatient Clinic, Auxilio Mutuo Hospital (San Juan), Damas Hospital (Ponce) and St. Luke's Hospital (Ponce). Participants (cases and controls) were all of Hispanic origin. An epidemiological questionnaire soliciting information and variables that were related to breast carcinoma risk was provided to each participant. Only cases with primary and metastatic breast carcinoma tumors (rather than secondary or other types of cancer) were studied. The pathology report from each patient was obtained in order to learn the tumor grade, tumor size, and other clinically relevant information.

Controls were women who had never been diagnosed with breast cancer and who were recruited consecutively from individuals visiting gynecological and primary-care medical offices in Puerto Rico for their routine mammography and other types of screening. There was a possibility that controls would have more weight than cancer cases; that potential confounding factor as well as any other confounding factors that became apparent were carefully analyzed and the properly adjustments made.<sup>16</sup> Controls

and cases were recruited from a population whose members all visited the same sites (clinics, physicians' offices, hospitals); any control who later developed breast cancer would be treated at the site from which she was recruited. Two main criteria determined the eligibility of controls: 1. any potential participant had to have had a normal clinical breast exam by her primary physician in the six months prior to enrollment, and 2. she had to have had a normal mammogram. These criteria reduced the likelihood of the existence of breast carcinoma among controls.

Approximately thirty milliliters of peripheral blood was obtained from each participant and stored in heparinized tubes. The lymphocytes were then isolated by the Ficoll gradient technique and suspended in freezing media containing 10% dimethyl sulfoxide, 40% RPMI-1640 medium, 50% fetal bovine serum, and 1% antibiotic/antimycotic the resulting solution was divided into 2.0 ml aliquots and stored in a freezer at  $-80^{\circ}\text{C}$ . These lymphocytes were later thawed in batches for DNA isolation. All of the samples came from Puerto Rican women, both with (205) and without (229) breast cancer, ranging in age from 22 to 80 years old. Only those with available DNA as of August 2009 were used for this study. There was no overall difference or differences among  $\leq 50$  and  $51 \geq$  subjects with respect to age, family history of breast cancer, body mass index, whether they ever had been pregnant, or number of live births among age-matched groups (Table 1). This lack of association between family history of breast cancer and age of onset has also been seen in other Hispanic populations.<sup>17</sup> Civil status was the same among age-matched controls, though the older women were more likely to be widows (Table 1).

ApoE genotyping was performed by polymerase chain reaction with the BioRad DNA Engine Thermal Cycler from the Molecular Biology Core Laboratory. Approximately 200 ng of purified DNA was required for a high-quality product. Reactions of 25  $\mu\text{L}$  were carried with a PCR Master Mix (Promega) Taq 50 U/mL, 400  $\mu\text{M}$  of e/a dNTPs, and 3 mM  $\text{MgCl}_2$ . The primers used were: (F4) 5'-ACAGAAT-TCGCCCCGGCCTGGTACAC-3' (1 mM) and (F6) 5'-TAAGCTTGGCACGGCTGTCCAAGG-3' (1 mM).<sup>18</sup> Reactions were denatured at  $95^{\circ}\text{C}$  for 5 min, followed by 35 cycles of primer annealing at  $60^{\circ}\text{C}$  for 1 min, extension at  $70^{\circ}\text{C}$  for 2 min, and

**Table 1.** Demographics of non-breast cancer and breast cancer patients.

	Non-breast cancer (22–50 yrs)	Breast cancer (22–50 yrs)	P-value	Non-breast cancer (51–89 yrs)	Breast cancer (51–89 yrs)	P-value
Age $\pm$ S.E.M. (n)	41.7 $\pm$ 0.6 (106)	43.0 $\pm$ 0.6 (63)	0.38	61.8 $\pm$ 0.8 (123)	63.8 $\pm$ 0.7 (142)	0.06
% Family history of breast cancer (n)	49.0 $\pm$ 0.1 (98)	42.6 $\pm$ 0.1 (61)	0.51	40.3 $\pm$ 0.05 (119)	34.5 $\pm$ 0.04 (139)	0.36
Body mass index (n)	26.5 $\pm$ 0.5 (104)	26.6 $\pm$ 0.6 (63)	0.89	27.9 $\pm$ 0.4 (123)	27.8 $\pm$ 0.5 (142)	0.86
% Ever been pregnant (n)	22.6 $\pm$ 0.05 (104)	25.4 $\pm$ 0.05 (63)	0.68	17.9 $\pm$ 0.03 (123)	18.3 $\pm$ 0.03 (142)	0.92
# Live births (n)	2.0 $\pm$ 0.1 (91)	2.3 $\pm$ 0.2 (55)	0.36	3.1 $\pm$ 0.2 (110)	2.8 $\pm$ 0.1 (125)	0.20
% Smoke (n)	11.6 $\pm$ 0.03 (103)	14.2 $\pm$ 0.04 (63)	0.63	12.5 $\pm$ 0.03 (120)	15.6 $\pm$ 0.03 (141)	0.47
% Alcohol (n)	37.6 $\pm$ 0.2 (93)	45.7 $\pm$ 0.2 (56)	0.79	43.7 $\pm$ 0.2 (112)	15.6 $\pm$ 0.03 (134)	0.25
Civil status (n)	105	63		122	142	
Married	67.4%	68.5%		65.5%	44.9%	
Single	22.0%	13.7%		13.8%	25.7%	
Divorced	9.6%	13.7%		17.2%	16.2%	
Widow	1.0%	4.0%		3.4%	13.2%	

denaturation at 95 °C for 1 min. This process was followed by a final extension of 10 min. After 3-hours of digestion with CfoI/HhaI (Promega), products were run on 4% agarose gel, and bands were identified by size according to restriction fragment length polymorphism.<sup>19</sup>

The frequency of overall apoE4 carriers within this population was 21.0% for women without breast cancer and 24.4% in breast cancer patients. There was no significant difference in frequency for any of the genotypes when grouping those with early-onset and late-onset breast cancer ( $p = 0.30$ ) and those similar to expected frequencies based on Caucasian populations. However, with a  $2 \times 2$  Analysis of Variance (ANOVA), when comparing subjects that were diagnosed at or

before the age of 50 versus those that were diagnosed at or after age 51 with appropriate controls, we found a significant differences in genotype ( $F = 5.43$ ,  $p < 0.02$ , Table 2). As seen in previous studies, in the late-onset breast cancer patients there were no differences in apoE allelic frequency.<sup>4,5</sup> In contrast, we found twice as many apoE3/apoE4 alleles in women who were 50 or younger, with a significant difference in those who are apoE carriers ( $F = 4.00$ ,  $p < 0.05$ , Table 2), and no change in the frequency with which the apoE2/apoE3 genotype is found. The odds ratio for the frequency of apoE4 in women 50 and under between non-breast cancer and breast cancer patient's was 2.15 (CI: 1.05–4.39). The apoE4 frequencies found in our population of early-onset individuals are

**Table 2.** Frequency of apoE genotypes in non-breast cancer and breast cancer patients.

	Non-breast cancer (21–50 yrs)	Breast cancer (21–50 yrs) <sup>1,2</sup>	Non-breast cancer (51–89 yrs)	Breast cancer (51–89 yrs)
n	106	63	123	142
apoE2/apoE2	0	0	0	0
apoE2/apoE3	10.4%	7.9%	6.5%	5.7%
apoE3/apoE3	74.0%	58.7%	70.7%	74.6%
apoE3/apoE4	14.4%	33.3%	22.0%	17.6%
apoE2/apoE4	1.9%	0	0	0
apoE4/apoE4	0.9%	0	0.8%	2.1%
Non-apoE4 carrier	81.1%	66.7%	77.2%	79.6%
apoE4 carrier	18.9%	33.3%	22.8%	20.4%

<sup>1</sup>Significant difference in allelic frequency ( $P < 0.02$ ).<sup>2</sup>Significant difference in frequency of apoE4 carriers ( $P < 0.05$ ).





the same as others found in an age-adjusted breast cancer population.<sup>20</sup> We also found that apoE4 was associated with decreased tumor size in younger women, but not with tumor grade (Table 3). As other studies have made 51 (as opposed to 50) the cut-off age for comparisons,<sup>21</sup> we repeated analysis and found the same significant effect (decreased tumor size) in early-onset breast cancer patients in terms of apoE genotype ( $F = 4.76$ ,  $p < 0.03$ ) and apoE4 allelic frequency ( $F = 3.95$ ,  $p < 0.05$ ). These data suggest that apoE4 may be a risk factor for the early onset of breast cancer and affect tumor size in Puerto Rican women who have breast cancer.

Particular genes like apoE also affect the response to chemotherapy and needed hormone treatment, which is an important factor to consider in the treatment of breast cancer. In Greek post-menopausal women, apoE4 carriers displayed reduced response to Tamoxifen.<sup>22</sup> Research suggests that knowing whether or not a patient's gene profile includes the apoE polymorphism is critical when pondering the risks and benefits of using estrogen in hormone therapy.<sup>23,24</sup> Studies on apoE as a potential genetic risk factor in breast cancer or lymphoma survivors found that even eight years after chemotherapy, apoE4 carriers displayed impairments specifically in visual memory, spatial ability, and psychomotor functioning.<sup>25</sup>

The current study suggests the importance of age of diagnosis as a factor in the relationship between apoE genotype and the risk for breast cancer. This study will need to be confirmed with additional ethnic/racial populations. Nonetheless, these findings suggest a strong association between apoE genotype and age of diagnosis of breast cancer in Puerto Rican women. There is a controversy concerning when women

should start getting mammograms; such tests are currently recommended for women between 45 and 50 years of age, depending on case and family history. This might turn out to be too late for some women, considering the fact that the highest incidence rate for ethnic minorities is age 50 and below and that those with early onset are likely to have more aggressive disease.<sup>26</sup> Our data indicates that studies on genetic markers in early-onset breast cancer patients may encourage women to rethink when they should start getting mammograms or other types of screening procedures.<sup>27,28</sup>

Knowing an individual's apoE genotype would allow the physician more information on how a patient may respond to hormones and chemotherapy if they are diagnosed. Taken together with past microarray analyses of single nucleotide polymorphisms in middle European white women,<sup>23</sup> our study supports the idea that breast cancer patients would benefit from health care professionals having access to their genetic profiles; such knowledge would aid in the design of treatment regimens as well as improve the effectiveness of genetic counseling.

## Acknowledgements

The study was funded by the Moffitt Cancer Center American Cancer Society—Institutional Research Grant (ACS-IRG) Program Award #93-032-13, project number 60-14599-01-01-S4; by a grant from the NCI Center to Reduce Health Disparities; and by NIH-MBRS Program grant S06 GM008239-20 to the Ponce School of Medicine through Dr. J. Matta. We would like to thank Dr. Julie Dutil's laboratory for providing isolated DNA from lymphocytes. Finally, thanks go to Bob Ritchie of the RCMI Publications Office (G12 RR003050). The authors also wish to

**Table 3.** Effects of apoE4 in breast cancer patients.

	Non-apoE4 carrier (22–50 yrs)	apoE4 carrier (22–50 yrs)	P-value	Non-apoE4 carrier (51–89 yrs)	apoE4 carrier (51–89 yrs)	P-value
n	30	18		90	20	
Grade 1	20.0%	16.7%		15.6%	20.0%	
Grade 2	46.7%	44.4%		47.8%	55.0%	
Grade 3	30.0%	38.9%		31.1%	25.0%	
Grade 4	3.3%	0		5.6%	0	
Total tumor grade	$2.2 \pm 0.1$	$2.6 \pm 0.4$	0.80	$61.8 \pm 0.8$	$63.8 \pm 0.7$	0.06
Tumor size	$2.5 \pm 0.4$	$1.2 \pm 0.3$	0.02 <sup>1</sup>	$2.2 \pm 0.2$	$1.8 \pm 0.4$	0.36

<sup>1</sup>Significant difference in tumor size.



acknowledge the support of PSM-Moffitt Cancer Center Partnership 5U56CA126379-04.

## Disclosures

This manuscript has been read and approved by all authors. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The authors and peer reviewers of this paper report no conflicts of interest. The authors confirm that they have permission to reproduce any copyrighted material.

## References

- Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. *Arch Intern Med*. 2003;163:49–56.
- De Angelis R, Tavilla A, Verdecchia A, et al. Breast cancer survivors in the United States: geographic variability and time trends, 2005–2015. *Cancer*. 2009;115:1954–66.
- Ripperger T, Gadzicki D, Meindl A, Schlegelberger B. Breast cancer susceptibility: current knowledge and implications for genetic counselling. *Eur J Hum Genet*. 2009;17:722–31.
- Yaylim I, Bozkurt N, Yilmaz H, Isbir T, Isik N, Arkan S. The apolipoprotein E epsilon 4 allele is not a risk factor for Turkish breast cancer patients. *Cancer Genet Cytogenet*. 2003;146:86–7.
- Niemi M, Kervinen K, Kiviniemi H, et al. Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. *J Epidemiol Community Health*. 2000;54:938–9.
- Zunarelli E, Nicoll JA, Migaldi M, Trentini GP. Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome. *Breast Cancer Res Treat*. 2000;63:193–8.
- Chang NW, Chen DR, Wu CT, et al. Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan. *Breast Cancer Res Treat*. 2005;90:257–61.
- Moore RJ, Chamberlain RM, Khuri FR. Apolipoprotein E and the risk of breast cancer in African-American and non-Hispanic white women. A review. *Oncology*. 2004;66:79–93.
- Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science*. 1988;240:622–30.
- Puerto Rico: Breast Cancer Incidence Rate per 100,000 Women. statehealthfacts.org. Kaiser Family Foundation., 2003.
- Figueroa NR, De la Torre T, Ortiz KJ, Perez J, Torres Me. Cancer of the Breast Stat Fact Sheet Puerto Rico Central Cancer Registry. San Juan, PR: Puerto Rico Department of Health, 2008.
- Phillips AA, Jacobson JS, Magai C, Considine N, Horowicz-Mehler NC, Neugut AI. Cancer incidence and mortality in the Caribbean. *Cancer Invest*. 2007;25:476–83.
- Ho GY, Figueroa-Valles NR, De La Torre-Feliciano T, et al. Cancer disparities between mainland and island Puerto Ricans. *Rev Panam Salud Publica*. 2009;25:394–400.
- Martinez-Cruzado JC, Toro-Labrador G, Ho-Fung V, et al. Mitochondrial DNA analysis reveals substantial Native American ancestry in Puerto Rico. *Hum Biol*. 2001;73:491–511.
- Martinez-Cruzado JC, Toro-Labrador G, Viera-Vera J, et al. Reconstructing the population history of Puerto Rico by means of mtDNA phylogeographic analysis. *Am J Phys Anthropol*. 2005;128:131–55.
- Szklo M, Nieto FJ. Epidemiology. Beyond the Basics. Second Edition edn. Boston: Jones and Bartlett Publishers, 2007.
- Risendal B, Hines LM, Sweeney C, et al. Family history and age at onset of breast cancer in Hispanic and non-Hispanic white women. *Cancer Causes Control*. 2008;19:1349–55.
- Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. *J Lipid Res*. 1990;31:545–8.
- Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. *Lancet*. 1991;337:1158–9.
- Moysich KB, Freudenheim JL, Baker JA, et al. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. *Mol Carcinog*. 2000;27:2–9.
- Romaguera J, Ortiz AP, Roca FJ, Colon G, Suarez E. Factors associated with metabolic syndrome in a sample of women in Puerto Rico. *Menopause*. 2010;23:388–39.
- Liberopoulos E, Karabina SA, Tselepis A, et al. Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? *Oncology*. 2002;62:115–20.
- Tempfer CB, Riener EK, Hefler LA, Huber JC, Muendlein A. DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy. *Fertil Steril*. 2004;82:132–7.
- Chang NW, Chen FN, Wu CT, Lin CF, Chen DR. Apolipoprotein E4 allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients. *Clin Chim Acta*. 2009;401:144–7.
- Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. *Psychooncology*. 2003;12:612–9.
- Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID, Jatoti I. Racial disparities in breast cancer outcome: insights into host-tumor interactions. *Cancer*. 2007;110:1880–8.
- Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. *JAMA*. 2009;302:1685–92.
- Justenhoven C, Hamann U, Schubert F, et al. Breast cancer: a candidate gene approach across the estrogen metabolic pathway. *Breast Cancer Res Treat*. 2008;108:137–49.

**Publish with Libertas Academica and every scientist working in your field can read your article**

*"I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely."*

*"The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I've never had such complete communication with a journal."*

*"LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought."*

**Your paper will be:**

- Available to your entire community free of charge
- Fairly and quickly peer reviewed
- Yours! You retain copyright

<http://www.la-press.com>